A 29-year-old Orlando man arrives at a local hospital for a scheduled orthopedic procedure. He is otherwise healthy, has no known history of serious medical problems, and expects to return home after a routine recovery.
Before surgery, the anesthesia team reviews his medical history. He reports that a distant relative once experienced a serious complication during surgery, but he does not know the details. The patient receives general anesthesia, and the operation begins without an apparent problem.
Approximately thirty minutes into the procedure, the anesthesia monitor begins showing an unexplained increase in end-tidal carbon dioxide. His heart rate rises, and the anesthesia provider increases ventilation in an attempt to correct the abnormal reading. Despite these adjustments, the carbon dioxide level remains elevated. The patient develops muscle rigidity, and his body temperature begins increasing rapidly.
The surgical team initially attributes the changes to inadequate ventilation and other possible causes. The procedure continues while additional adjustments are made to the anesthesia equipment. By the time the team recognizes that the patient may be experiencing malignant hyperthermia, he has developed severe metabolic acidosis, dangerously elevated potassium, and an abnormal heart rhythm.
The anesthesia team discontinues the triggering medications and begins emergency treatment with dantrolene, but the patient's condition deteriorates into cardiac arrest. Although circulation is restored, the patient suffers a significant brain injury from inadequate oxygen delivery during the emergency. He requires intensive care and prolonged rehabilitation.
His family later questions whether earlier recognition of the warning signs and faster treatment could have prevented the catastrophic outcome.
This hypothetical scenario illustrates a serious question in Orlando medical malpractice cases: When does a failure to recognize and promptly treat malignant hyperthermia during anesthesia constitute medical negligence?
Contact us today through our free case evaluation form or call 877-644-5122.
What Is Malignant Hyperthermia?
Malignant hyperthermia is a rare, potentially fatal reaction to certain medications used during general anesthesia. The condition occurs in people who have an underlying susceptibility involving the regulation of calcium within skeletal muscle cells.
When exposed to triggering anesthetic medications, susceptible patients may experience uncontrolled calcium release inside muscle cells. This causes an extreme increase in muscle metabolism, oxygen consumption, carbon dioxide production, and heat generation. As the reaction progresses, patients may develop muscle rigidity, metabolic acidosis, dangerously elevated body temperature, abnormal heart rhythms, and damage to major organs.
Without prompt recognition and treatment, malignant hyperthermia can progress to cardiac arrest or death. The National Library of Medicine's clinical review of malignant hyperthermia describes the condition as a life-threatening anesthesia emergency requiring immediate intervention.
The fact that malignant hyperthermia is rare does not make it unimportant. Anesthesia professionals must be prepared to recognize and respond to this potentially catastrophic complication.
Why Malignant Hyperthermia Is So Dangerous
During a malignant hyperthermia crisis, skeletal muscle cells begin consuming energy at an abnormally high rate. This excessive metabolic activity increases oxygen demand and produces large amounts of carbon dioxide and heat. As the reaction continues, the body's normal mechanisms for maintaining chemical balance become overwhelmed.
The patient may develop severe respiratory and metabolic acidosis, meaning that the blood becomes dangerously acidic. Muscle cells can begin breaking down, releasing potassium and other substances into the bloodstream. Elevated potassium can disrupt the heart's electrical activity and cause life-threatening arrhythmias.
The combination of metabolic abnormalities, cardiovascular instability, and muscle destruction can lead to kidney failure, cardiac arrest, and multiple organ dysfunction. The 2025 Japanese Society of Anesthesiologists guideline for malignant hyperthermia emphasizes that early recognition and immediate treatment are essential because deterioration can occur rapidly.
Which Anesthesia Medications Can Trigger Malignant Hyperthermia?
Malignant hyperthermia is associated with exposure to specific triggering anesthetic agents. These include volatile inhaled anesthetics, such as sevoflurane, desflurane, and isoflurane, as well as succinylcholine, a depolarizing neuromuscular blocking medication. These medications are widely used in appropriate clinical settings and can be administered safely to patients who are not susceptible to malignant hyperthermia.
The problem arises when a susceptible individual experiences an abnormal physiological response. Many commonly used intravenous anesthetic medications, including propofol, are not malignant hyperthermia triggers. For patients known or strongly suspected to be susceptible, anesthesia teams can develop plans using non-triggering medications and appropriately prepared equipment.
An Orlando anesthesia malpractice investigation may examine whether a known susceptibility was recognized before surgery and whether the selected anesthetic plan was appropriate.
What Are the Early Warning Signs of Malignant Hyperthermia?
Malignant hyperthermia does not always begin with a dramatically elevated body temperature. In fact, some of the earliest signs may involve changes in ventilation, carbon dioxide production, and heart rate. An unexplained rise in end-tidal carbon dioxide can be an important warning sign, particularly when it persists despite increased ventilation.
Other findings may include rapid heart rate, muscle rigidity, increased oxygen consumption, and metabolic acidosis. As the crisis progresses, body temperature may rise rapidly. Patients can develop abnormal heart rhythms, elevated potassium, and signs of muscle breakdown. The 2025 anesthesia guideline identifies unexplained increases in end-tidal carbon dioxide, tachycardia, muscle rigidity, and rapidly rising temperature among the clinical findings that should prompt immediate evaluation for malignant hyperthermia.
Not every patient develops these findings in the same order. The challenge for anesthesia professionals is recognizing the developing pattern before the crisis causes irreversible injury.
Why Elevated End-Tidal Carbon Dioxide Matters
End-tidal carbon dioxide, often abbreviated ETCO2, measures the concentration of carbon dioxide in exhaled gas at the end of a breath. During general anesthesia, this measurement provides important information about ventilation and the patient's physiological condition. In malignant hyperthermia, skeletal muscles begin producing excessive amounts of carbon dioxide because of uncontrolled metabolic activity.
As a result, the end-tidal carbon dioxide level may rise despite efforts to increase ventilation. This can be one of the earliest and most significant warning signs. However, elevated carbon dioxide can also result from other causes, including inadequate ventilation, equipment problems, and certain surgical circumstances.
An anesthesia provider must evaluate the possible explanations while remaining alert to malignant hyperthermia when the overall clinical picture is concerning. A malpractice investigation may examine whether the anesthesia team recognized a persistent unexplained increase in ETCO2 and responded appropriately.
Why Waiting for a High Fever Can Be Dangerous
The name malignant hyperthermia emphasizes elevated body temperature, but significant hyperthermia may develop after other abnormalities have already appeared. A patient can experience dangerous metabolic changes before the temperature reaches an extreme level.
If an anesthesia team waits for a very high fever before considering malignant hyperthermia, an important opportunity for early treatment may be lost. The condition should be considered when the clinical findings are consistent with a developing hypermetabolic crisis, particularly after exposure to known triggering medications.
The National Library of Medicine emphasizes the importance of recognizing early signs and promptly initiating treatment rather than allowing the reaction to progress. In a potential Orlando medical malpractice case, experts may examine whether treatment was delayed because the team expected fever to appear before making the diagnosis.
What Is Muscle Rigidity During Malignant Hyperthermia?
Muscle rigidity is another important clinical feature of malignant hyperthermia.
Some patients develop generalized muscle rigidity, while others exhibit pronounced tightening of the jaw muscles.
Jaw muscle rigidity, sometimes called masseter muscle rigidity, may occur after administration of succinylcholine.
However, not every episode of jaw stiffness represents malignant hyperthermia, and not every patient with malignant hyperthermia develops obvious rigidity.
The significance depends on the surrounding circumstances, including the medications administered and the presence of other abnormal findings.
When rigidity occurs alongside unexplained hypercarbia, tachycardia, or metabolic acidosis, it may increase concern for malignant hyperthermia.
A malpractice investigation may examine whether the anesthesia team appropriately evaluated and responded to these findings.
Why Anesthesia Monitoring Is Essential
Patients receiving general anesthesia cannot communicate symptoms such as pain, weakness, or an unusual sensation of overheating.
Anesthesia professionals must therefore rely on continuous monitoring and clinical assessment to identify developing complications.
Important measurements may include heart rate, blood pressure, oxygen saturation, end-tidal carbon dioxide, ventilation parameters, and temperature when indicated.
The anesthesia record may document changes in these measurements throughout the procedure.
These trends can be especially important when investigating a suspected malignant hyperthermia crisis.
For example, a progressive rise in ETCO2 followed by unexplained tachycardia and increasing temperature may reveal a pattern that required prompt evaluation.
A medical malpractice investigation may examine whether monitoring was appropriate, whether abnormalities were recognized, and whether the response was timely.
How Is Malignant Hyperthermia Diagnosed During Surgery?
During an acute crisis, malignant hyperthermia is primarily a clinical diagnosis. Anesthesia professionals assess the patient's symptoms, physiological changes, medication exposure, and response to treatment. Laboratory studies may reveal metabolic acidosis, elevated potassium, increased creatine kinase, or evidence of muscle breakdown.
However, waiting for confirmatory laboratory results before beginning emergency treatment may create a dangerous delay when malignant hyperthermia is strongly suspected. The 2025 anesthesia guideline emphasizes that treatment should begin immediately when the clinical findings indicate a suspected malignant hyperthermia crisis.
Later testing may help establish whether the patient has an inherited susceptibility. In a malpractice investigation, experts may examine whether the anesthesia team acted on the clinical evidence available at the time rather than waiting for certainty while the patient deteriorated.
What Is Dantrolene?
Dantrolene is the principal medication used to treat malignant hyperthermia. It works by reducing abnormal calcium release within skeletal muscle cells, helping interrupt the uncontrolled metabolic reaction. The medication is administered intravenously during an acute crisis.
The Malignant Hyperthermia Association of the United States (MHAUS) provides educational resources and emergency treatment recommendations for malignant hyperthermia. MHAUS treatment guidance describes an initial intravenous dantrolene dose of 2.5 mg/kg, with additional doses administered according to the patient's clinical response.
The exact treatment regimen depends on the patient's condition and the emergency protocol being followed. Dantrolene is not a substitute for other emergency measures, but prompt administration is a critical component of treatment.
Why Delayed Dantrolene Treatment Can Be Devastating
When malignant hyperthermia is suspected, time is an important factor. The uncontrolled metabolic reaction can continue damaging muscles, disrupting electrolyte levels, and placing severe stress on the cardiovascular system. Delaying dantrolene may allow these abnormalities to worsen.
A patient who initially exhibits elevated carbon dioxide and tachycardia may subsequently develop severe hyperkalemia, cardiac arrhythmias, or circulatory collapse. A malpractice investigation may examine when malignant hyperthermia should reasonably have been suspected, when dantrolene was requested, and when the first dose was administered.
Experts may also evaluate whether earlier administration probably would have prevented or reduced the patient's injuries.
Why Triggering Anesthesia Medications Must Be Stopped
One of the first steps in responding to suspected malignant hyperthermia is discontinuing the triggering anesthetic agents. Continuing exposure can sustain the abnormal muscle reaction. The anesthesia team must transition to an appropriate non-triggering anesthetic technique if anesthesia remains necessary.
Emergency management also involves delivering high-concentration oxygen, increasing ventilation, obtaining assistance, and initiating dantrolene treatment. The team may need to stop or abbreviate the surgical procedure when clinically feasible.
The appropriate response depends on the patient's condition and the nature of the operation. A malpractice investigation may examine whether the triggering medications were promptly discontinued and whether the anesthesia team followed an appropriate emergency response.
Should Orlando Surgical Facilities Have Dantrolene Available?
Facilities that administer malignant hyperthermia-triggering anesthetics must be prepared to respond to an acute crisis. This includes appropriate emergency medications, equipment, staff training, and response procedures.
MHAUS publishes recommendations addressing dantrolene availability and preparedness for facilities where triggering anesthetics are used. An investigation may examine whether dantrolene was available in sufficient quantities, whether staff could access it promptly, and whether the facility had an established malignant hyperthermia response plan.
The applicable standard depends on the facility's services, medication practices, and other circumstances. These issues may arise in Orlando hospitals, ambulatory surgery centers, and other facilities administering general anesthesia. A shortage of medication or an avoidable delay in locating emergency supplies may become relevant when it contributes to a patient's injuries.
Why Team Communication Matters During an Anesthesia Emergency
A malignant hyperthermia crisis requires a coordinated response. Anesthesia professionals, surgeons, nurses, pharmacists, and other personnel may need to perform multiple tasks simultaneously.
One team member may prepare dantrolene while another manages ventilation and monitoring. Others may obtain laboratory testing, arrange cooling measures, or prepare for intensive care transfer. Clear communication is essential to coordinating these activities. Delays can occur when team members fail to recognize the emergency, responsibilities are unclear, or critical information is not communicated promptly.
In an Orlando medical malpractice investigation, experts may examine whether communication or organizational failures contributed to delayed treatment.
How Malignant Hyperthermia Can Cause Cardiac Arrest
As malignant hyperthermia progresses, the patient may develop severe metabolic disturbances that interfere with normal heart function. One major concern is hyperkalemia, an abnormally elevated potassium concentration in the blood. Potassium plays a critical role in the electrical activity of the heart.
When potassium rises to dangerous levels, patients may develop serious arrhythmias and cardiac arrest. Acidosis and other physiological abnormalities can further compromise cardiovascular stability. Prompt recognition and treatment of the underlying malignant hyperthermia crisis are essential, along with appropriate management of life-threatening electrolyte and cardiac complications.
A malpractice investigation may examine whether delayed treatment contributed to the development of cardiac arrest.
Can Malignant Hyperthermia Cause Brain Injury?
Yes. Severe malignant hyperthermia can contribute to brain injury through several mechanisms. If the patient experiences cardiac arrest, prolonged circulatory instability, or inadequate oxygen delivery, the brain may suffer hypoxic-ischemic injury. The severity of the neurological outcome depends on the duration and extent of impaired oxygen delivery, the patient's underlying condition, and the effectiveness of resuscitation.
Some patients recover without permanent neurological damage, while others experience significant cognitive or physical impairments. In a medical malpractice case, experts may evaluate whether earlier recognition and treatment probably would have prevented cardiac arrest or reduced the severity of the resulting brain injury.
What Is Rhabdomyolysis?
Rhabdomyolysis occurs when skeletal muscle cells break down and release their contents into the bloodstream. Malignant hyperthermia can cause extensive muscle injury because of the extreme metabolic activity occurring within muscle cells. Substances released during muscle breakdown include myoglobin, which can contribute to kidney damage.
Laboratory testing may reveal elevated creatine kinase and other abnormalities. Patients may also develop dark-colored urine and electrolyte disturbances. Severe rhabdomyolysis can require intensive monitoring and treatment.
A malpractice investigation may examine whether delayed control of the malignant hyperthermia reaction contributed to extensive muscle breakdown and subsequent complications.
How Malignant Hyperthermia Can Cause Kidney Failure
The kidneys may be affected by several complications associated with malignant hyperthermia. Severe muscle breakdown releases myoglobin, which can damage kidney tissue. Dehydration, circulatory instability, and other metabolic abnormalities may further reduce kidney function. Some patients develop acute kidney injury requiring specialized treatment or temporary dialysis.
In severe cases, kidney impairment may persist after the initial crisis resolves. A malpractice investigation may examine whether earlier treatment would probably have limited muscle injury, maintained circulation, and reduced the risk of kidney damage.
Why Patients Need Monitoring After the Initial Crisis
Successful initial treatment does not eliminate every risk associated with malignant hyperthermia. Some patients experience recurrence of symptoms after the initial reaction has improved.
For that reason, patients who experience a malignant hyperthermia crisis require continued monitoring in an appropriately equipped setting. The 2025 anesthesia guideline recommends monitoring for at least twenty-four hours after an acute episode. The appropriate duration and intensity of care depend on the patient's condition and the severity of the reaction.
A malpractice investigation may examine whether the patient received appropriate postoperative monitoring and whether recurrent symptoms were promptly recognized and treated.
Can Malignant Hyperthermia Occur During Outpatient Surgery?
Yes. Malignant hyperthermia can occur during procedures performed in hospitals or outpatient surgical facilities when triggering anesthetic medications are administered. The condition is not limited to lengthy or complex operations.
A patient undergoing an otherwise routine orthopedic, dental, or other procedure under triggering general anesthesia may experience a malignant hyperthermia crisis. Outpatient facilities must consider the risks associated with the anesthetic medications they administer and maintain appropriate emergency preparedness.
An investigation may examine whether the facility had the necessary medications, equipment, training, and transfer procedures to respond to a malignant hyperthermia emergency.
What If the Patient Had a Family History of Anesthesia Complications?
Malignant hyperthermia susceptibility is frequently inherited. Certain genetic variants, particularly those involving the RYR1 gene, are associated with increased susceptibility. A family history of unexplained anesthesia complications, severe muscle rigidity, or a suspected malignant hyperthermia episode may therefore be clinically important.
Patients may not know the precise diagnosis experienced by a relative. For this reason, preoperative assessment may require further questions when a patient reports a concerning family history. The anesthesia team may need to review available records, seek specialist guidance, or develop a non-triggering anesthetic plan.
A malpractice investigation may examine whether relevant family history was obtained, documented, and appropriately considered before surgery.
Can a Patient Have Malignant Hyperthermia After Previous Uneventful Surgeries?
Yes. A patient may undergo anesthesia on one or more occasions without experiencing malignant hyperthermia and later develop a reaction during another procedure. Previous uneventful exposure does not conclusively establish that a person lacks susceptibility.
The development of a crisis can depend on multiple factors, including the triggering agents used and the circumstances of exposure. A malpractice investigation may examine whether the anesthesia team improperly dismissed a concerning family history solely because the patient had previously tolerated anesthesia.
How Is Malignant Hyperthermia Susceptibility Confirmed?
After an acute episode, patients may undergo specialized evaluation to determine whether they have malignant hyperthermia susceptibility. Testing may include genetic evaluation for relevant variants and, in selected circumstances, a specialized muscle biopsy contracture test.
These tests are not substitutes for emergency treatment during a suspected crisis. Their primary purpose is to help clarify future anesthesia risks and guide care for the patient and potentially affected family members.
The National Library of Medicine's GeneReviews resource on malignant hyperthermia susceptibility discusses genetic causes, diagnostic evaluation, and recommendations for susceptible individuals. A patient who survives a suspected malignant hyperthermia episode should receive appropriate information about future anesthesia precautions.
When Can Failure to Recognize Malignant Hyperthermia Become Orlando Medical Malpractice?
The occurrence of malignant hyperthermia does not automatically establish medical negligence. A susceptible patient may experience a reaction despite an appropriate preoperative evaluation and careful anesthesia management.
Under Florida Statute § 766.102, a medical malpractice claimant must establish that a healthcare provider breached the prevailing professional standard of care and that the breach proximately caused the claimed injury.
In an Orlando malignant hyperthermia case, qualified medical experts may evaluate whether the anesthesia provider obtained an appropriate history, recognized concerning monitoring changes, discontinued triggering agents, and initiated emergency treatment promptly. Experts may also examine whether dantrolene was available, whether staff responded appropriately, and whether the patient received necessary postoperative care.
Cases involving these failures may raise issues of Orlando hospital malpractice or negligence by individual anesthesia professionals. The applicable standard depends on the healthcare provider's responsibilities and the circumstances of the emergency.
Causation: Would Earlier Treatment Have Prevented the Injury?
Establishing that the anesthesia team should have recognized malignant hyperthermia earlier is only part of a medical malpractice claim. The claimant must also prove that the alleged delay caused additional injury. Suppose an Orlando patient develops progressively elevated end-tidal carbon dioxide, unexplained tachycardia, and muscle rigidity during surgery.
The team does not recognize malignant hyperthermia until the patient develops severe hyperkalemia and cardiac arrest.
Medical experts may need to determine when the clinical findings should reasonably have prompted emergency treatment. Would earlier discontinuation of triggering agents and dantrolene administration probably have prevented the cardiac arrest? Would faster treatment have reduced muscle breakdown or kidney injury? Was the patient's neurological injury caused by the delay or by complications that could not reasonably have been prevented?
These questions require careful analysis of the anesthesia record, physiological measurements, medication administration times, and the patient's subsequent course.
The Anesthesia Record Can Reveal Missed Opportunities
Malignant hyperthermia malpractice cases often depend on reconstructing the sequence of events minute by minute.
Consider a hypothetical Orlando surgical procedure in which the patient's end-tidal carbon dioxide begins rising at 9:15 a.m.
By 9:20 a.m., the patient's heart rate has increased significantly, and additional ventilation has not corrected the carbon dioxide abnormality.
At 9:25 a.m., muscle rigidity becomes apparent.
At 9:30 a.m., the patient develops a rapidly increasing temperature and worsening metabolic abnormalities.
The team does not administer dantrolene until 9:45 a.m.
A malpractice investigation may examine whether the earlier findings should have prompted suspicion of malignant hyperthermia and whether the interval before treatment contributed to the patient's injuries.
The timeline alone does not establish negligence. Qualified experts must interpret the findings in light of the circumstances and the information available to the treating team.
What Evidence Matters in an Orlando Malignant Hyperthermia Malpractice Investigation?
A thorough investigation may require review of the preoperative anesthesia assessment, medication records, intraoperative monitoring data, and the complete anesthesia record. The investigation may also examine the surgical report, nursing notes, laboratory findings, and documentation of emergency interventions. Records concerning dantrolene availability, medication preparation, and administration times may be particularly important.
If the patient suffered cardiac arrest, resuscitation records and intensive care documentation may help establish the duration and severity of the event. Neurological imaging, rehabilitation records, and specialist evaluations may provide information about any resulting brain injury. Medical experts may use these materials to determine whether the reaction was recognized and treated in accordance with the applicable standard of care.
Can a Hospital or Surgery Center Be Responsible for an Inadequate Emergency Response?
Some malignant hyperthermia cases involve institutional failures rather than a single clinician's diagnostic decision. A facility may lack adequate emergency medication supplies, have poorly organized equipment, or fail to maintain an effective response protocol. Staff members may not know where dantrolene is stored or how to prepare it promptly.
Communication problems may delay requests for assistance or transfer to a higher level of care. These circumstances can raise questions about the facility's responsibilities and whether its policies and practices met the applicable standard of care. An investigation may examine whether institutional failures contributed to the severity of the patient's injuries.
The Long-Term Consequences of Malignant Hyperthermia
Patients who survive a severe malignant hyperthermia crisis may experience substantial long-term consequences. Some recover fully after prompt treatment. Others experience complications such as kidney injury, muscle damage, neurological impairment, or reduced physical endurance.
Patients who suffer cardiac arrest may require extensive rehabilitation and ongoing medical care. A person who previously worked full time may be unable to return to employment because of cognitive or physical limitations. The patient may also need specialized anesthesia planning for future procedures.
In an Orlando medical malpractice case, experts may evaluate medical expenses, future treatment needs, lost earning capacity, rehabilitation costs, and other legally recoverable damages.
When Malignant Hyperthermia Results in Wrongful Death
Malignant hyperthermia can be fatal when the reaction progresses to severe metabolic instability, cardiac arrest, or multiple organ failure. When a patient dies during or after surgery, surviving family members may question whether the anesthesia team recognized the emergency and provided appropriate treatment.
A wrongful death investigation may examine the medications administered, the sequence of physiological changes, the timing of dantrolene treatment, and the availability of emergency resources. The fact that a patient died from malignant hyperthermia does not automatically establish medical malpractice.
The evidence must support both a breach of the applicable standard of care and a causal relationship between that breach and the death.
Orlando Medical Malpractice Claims Require Presuit Investigation
Florida imposes specific procedural requirements on medical negligence claims, including those arising from anesthesia care at Orlando hospitals and surgical facilities.
Under Florida Statute § 766.203, a claimant must conduct a reasonable presuit investigation before issuing notice of intent to initiate medical negligence litigation.
The investigation must establish reasonable grounds to believe that a prospective defendant was negligent and that the negligence caused injury, supported by a verified written medical expert opinion meeting Florida's statutory requirements.
A malignant hyperthermia case may require expert review by anesthesiologists, critical care physicians, hospital administrators, or other appropriately qualified professionals. The relevant experts depend on the alleged failures, the responsibilities of the healthcare providers, and the nature of the patient's injuries.
Florida also imposes deadlines and additional procedural requirements on medical malpractice claims, making timely legal evaluation important.
A Serious Anesthesia Complication Does Not Automatically Establish Negligence
Malignant hyperthermia is a rare but dangerous reaction that can occur even when healthcare providers exercise appropriate care. Some patients have no known family history or prior warning signs of susceptibility. Others develop rapidly progressive reactions despite prompt recognition and treatment.
For these reasons, the fact that a patient experienced malignant hyperthermia, required intensive care, suffered organ damage, or died does not automatically establish medical malpractice.
A proper investigation must determine whether the anesthesia team recognized the warning signs, responded appropriately, and provided treatment consistent with the prevailing professional standard of care.
It must also determine whether any alleged failure probably caused additional injury. These questions require careful review of the medical evidence and qualified expert analysis.
Talk to an Orlando Medical Malpractice Attorney
Malignant hyperthermia is a potentially fatal anesthesia emergency that requires rapid recognition and treatment. When healthcare providers fail to identify concerning changes in carbon dioxide levels, heart rate, muscle rigidity, or temperature, delayed intervention may contribute to cardiac arrest, organ failure, permanent brain injury, or death.
At Bounds Law Group, we focus exclusively on medical malpractice cases. Our attorneys represent patients and families in Orlando, Orange County, and throughout Central Florida in cases involving anesthesia errors, surgical complications, hospital negligence, catastrophic brain injuries, and wrongful death.
If you or a loved one suffered serious injuries after an anesthesia team failed to recognize or appropriately treat malignant hyperthermia at an Orlando-area hospital or surgical facility, contact Bounds Law Group for a confidential, free consultation. Our attorneys can review the anesthesia records, reconstruct the treatment timeline, and consult qualified medical experts to determine whether preventable medical negligence contributed to the outcome.
Contact us today through our free case evaluation form or call 877-644-5122.